L1 Therapeutics

Mission

L1 Therapeutics is a biotechnology company focused on developing genomics‑guided therapeutic strategies that target endogenous LINE‑1 (Long Interspersed Nuclear Element‑1) activity as a modifiable biological driver of disease

The company’s initial focus is in cancer, where whole‑genome sequencing enables identification of tumors in which LINE‑1 retrotransposition remains biologically active and therapeutically actionable. In these contexts, L1 Therapeutics is developing approaches that integrate genomic stratification with coordinated therapeutic intervention to selectively suppress LINE‑1‑associated genome instability

The rapidly declining cost of whole‑genome sequencing now makes prospective identification of tumors with therapeutically actionable LINE‑1 activity feasible at scale

L1 Therapeutics is currently developing preclinical studies to support investigational new drug applications

Technology

Tumor genomes often exhibit multiple sources of genomic instability, not all of which are therapeutically addressable at every stage of disease. L1 Therapeutics focuses on identifying disease contexts in which LINE‑1 activity represents a distinguishable and actionable contributor to ongoing genomic or cellular stress

Using tumor‑derived whole‑genome sequencing, we are using genomic stratification approaches that distinguish LINE‑1‑associated tumor evolution from alternative dominant drivers

In tumors meeting these criteria, we are developing combination therapy strategies that pair targeted inhibition of LINE‑1 activity with anticancer treatments known to induce cellular stress, with the goal of constraining therapy‑associated tumor evolution while enhancing the durability and effectiveness of standard‑of‑care treatments

Our intellectual property is supported by pending U.S. and international patent filings covering genomic stratification and LINE‑1‑directed combination therapy approaches

Partnerships

L1 Therapeutics is advancing its therapeutic strategy with the intent to collaborate with pharmaceutical, and diagnostics partners

Team

L1 Therapeutics was founded by William Brandler, who trained in Natural Sciences at the University of Cambridge and earned a PhD in Human Genomics from the University of Oxford. His background spans cancer genomics and computational biology, with over a decade of experience applying large‑scale genomic data to the study of disease biology in academic and industry settings

L1 Therapeutics works with scientific advisors including Alysson Muotri, Professor at the University of California, San Diego, and RORR Consulting, whose CEO is Richard Ogden

Contact

For scientific, partnering, or investment inquiries:

Loading contact…